Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia

Exclusion Criteria

• •LDL-C levels \> 250 mg/dL (6.48 mmol/L)
• •Triglycerides \>350 mg/dL (3.95 mmol/L)
• •Conditions / situations such as:
• •* presence of any clinically significant uncontrolled endocrine disease known to influence lipids levels
• •* Active liver disease
• •* Recent history of congestive heart failure , of unstable angina pectoris, myocardial infarction, coronary bypass surgery or angioplasty, or Unstable or severe peripheral artery disease
• •* Positive test for Hepatitis B surface antigen and/or Hepatitis C antibody or Known to be Human Immunodeficient Virus (HIV) positive
• •Pregnant or breast-feeding women,
• •Women of childbearing potential not protected by effective contraceptive method of birth control (including oral contraceptives) and/or who are unwilling or unable to be tested for pregnancy prior to exposure to the Investigational Product
• •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.